One-Time radiation during surgery could spare older breast cancer patients weeks of treatment
NCT ID NCT04414202
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at giving a single dose of radiation directly to the tumor site during breast-conserving surgery in women aged 60 and older with early-stage, hormone-sensitive breast cancer. The goal is to see if this shorter, targeted approach controls the cancer as well as standard weeks-long whole-breast radiation. Researchers are tracking local relapse rates and cosmetic outcomes in 519 participants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- intra-operative partial irradiation (radiation therapy given during surgery)
- What this could lead to
- If successful, this could offer a shorter, more convenient radiation option for older women with early-stage breast cancer, reducing treatment time from weeks to a single dose.
- What could go wrong
- This is an observational study, not a randomized trial, so results may not prove the approach is as effective as standard whole-breast radiation. Long-term local relapse rates are still being tracked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
519 people
The number who actually took part.
- Started
-
Dec 2009
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery
- Ages
-
60 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women 60 years of age or older, * Histologically proven invasive ductal breast cancer or of a histologically favorable sub-type (mucinous, tubular or colloid), -. Unifocal tumor, * T1 (diameter ≤ 20 mm), * N0 (pN0 or pNi+), * M0, * Gland exeresis margins ≥ 2 mm, * Estrogen receptor positive, * Information and non-opposition of the patient. Exclusion Criteria: -. Inflammatory breast cancer, * Associated peri-tumoral lymphatic emboli * Associated extensive intra-ductal component * Invasive lobular carcinoma * Pure ductal carcinoma in situ, * Sarcoma or lymphoma-type non-epithelial tumor * Synchronous bilateral breast cancer, * Any prior neo-adjuvant treatment: radiotherapy, chemotherapy, hormone therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast conserving surgery are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icm Val D'Aurelle
Montpellier, Herault, 34398, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Microscope aims to spare breast cancer patients a second surgery
- Can sound waves replace the scalpel for breast cancer?
- Can fewer, stronger radiation doses match standard treatment after mastectomy?
- Can radiation before or after breast reconstruction improve outcomes?
- Two biopsy methods together may spare some breast cancer patients a bigger surgery
- Personalized chemo: could tumor DNA hold the key to better breast cancer treatment?